Clinical Trial

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-02
notable Primary completion pushed: 2031-06-30 -> 2031-07-30 2026-07-02
minor Completion pushed: 2031-09-30 -> 2031-10-30 2026-07-02
Trial Details
NCT Number NCT07629115
Lead Sponsor Innopeutics Corporation
Conditions Parkinson Disease, Parkinson's Disease
Enrollment 6 participants
Start Date 2026-05-29
Primary Completion 2031-07-30 (estimated)
Study Completion 2031-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01